Sign Up to like & get
recommendations!
1
Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15544
Abstract: Preclinical studies showed that capmatinib reversibly inhibits cytochrome P450 (CYP) 3A4 and CYP1A2 in a time‐dependent manner. In this study, we evaluated the effect of capmatinib on the exposure of sensitive substrates of CYP3A (midazolam)…
read more here.
Keywords:
substrates cyp3a;
cyp1a2 caffeine;
capmatinib;
midazolam cyp1a2 ... See more keywords